Tenax Therapeutics receives USPTO Notice of Allowance for oral levosimendan patent in PH-HFpEF

TENAX THERAPEUTICS, INC.

Patent covers oral levosimendan (TNX-103) for PH-HFpEF; term through Dec 2040, possible extension beyond.
No FDA-approved treatments exist for PH-HFpEF, affecting >1.6M North Americans, projected >2M by 2030.
Phase 2 HELP study showed levosimendan improved 6-minute walk by 29 meters (p=0.03) vs placebo.
Tenax intends to initiate Phase 3 trial of oral formulation in 2023; FDA agreed 6-minute walk test as primary endpoint.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.